WO1992014476A1

WO1992014476A1 - Method of treating pulmonary inflammation

Info

Publication number: WO1992014476A1
Application number: PCT/US1992/001398
Authority: WO
Inventors: Robert Joseph Sturm; Laurel Moore Adams; Barry Michael Weichman
Original assignee: American Home Products Corporation
Priority date: 1991-02-22
Filing date: 1992-02-21
Publication date: 1992-09-03
Also published as: IL100905A0; DK0573584T3; SG52403A1; HK1011284A1; LV12400B; ZA921211B; PT100144A; JP2673168B2; IE920554A1; PT100144B; KR100201516B1; ATE183647T1; US5080899A; EP0573584B1; EP0573584A4; DE69229858D1; EP0573584A1; DE69229858T2; IL100905A; KR930703000A

Abstract

This invention provides a pharmaceutical composition for preventing or reversing pulmonary inflammation in a mammal comprising rapamycin prepared by processes known per se and if desired a pharmaceutically acceptable carrier, diluent or excipient; said composition being adapted for administration orally, parenterally, nasally, or intrabronchially. As such, rapamycin is useful in providing the symptomatic relief of diseases in which pulmonary inflammation is a component, such as, asthma, chronic obstructive pulmonary disease, emphysema, acute respiratory distress syndrome, bronchitis, and the like.

Description

METHOD OF TREATING PULMONARY INFLAMMATION

This invention relates to the preparation of pharmaceutical compositions, in particular compositions containing rapamycin.

Asthma has recently been recognized as being mediated by an inflammatory response in the respiratory tract [DeMonchy, J., Am, Rev. Resp. Dis. 131: 373-376 (1985)]. Recent findings suggest that human T-lymphocytes play a major role in regulating the airway inflammation associated with allergic asthma [Frew, A.J., J. Allergy Clin. Immunol. £5.: 533-539 (1990)] and chronic obstructive pulmonary disease [O'Connor, G.T., Am. Rev. Resp. Dis. J4Q: 225-252 (1989)].

In addition to the infiltration of other inflammatory cells into the pulmonary system, human asthmatics and atopies who are dual responders (i.e., show both early and late phase reactions) show a small but significant infiltration of T-lymphocytes following antigen challenge [Frew, AJ. and Kay, A.B., J. Immunol. 141: 4158-4164 (1988)]. More importantly, these recruited T-lymphocytes are almost entirely of the CD4⁺ (T-helper) type, and there appears to be a direct correlation between the influx of CD4+ cells, the influx of eosinophils, and the IgE-related allergic response in these individuals [Frew, AJ. and Kay, A.B., J. Immunol. 141: 4158-4164 (1988)]. In severe asthmatics, these CD4+ cells appear to be activated [Corrigan, CJ. and Kay, A.B., Am. Rev. Resp. Dis. 14 970-977 (1990)] by virtue of the increase in IL-2 receptor positive cells. Thus, these cells are capable of producing cytokines (such as IL-3, IL-5, and granulocyte macrophage colony stimulating factor) which can directly affect the differentiation, maturation and activation state of the eosinophils and other inflammatory cells.

Rapamycin, a macrocyclic triene antibiotic produced by Streptomvces hygroscopicus [U.S. Patent 3,929,992] has been shown to prevent the formation of humoral (IgE-like) antibodies in response to an albumin allergic challenge [Martel, R., Can. J. Physiol. Pharm. 55: 48 (1977)], inhibit murine T-cell activation [Strauch, M., FASEB 3: 3411 (1989)], and prolong survival time of organ grafts in histoincompatable rodents [Morris, R., Med. Sci. Res. 17: 877 (1989)].

This invention provides a pharmaceutical composition for preventing or reversing pulmonary inflammation in a mammal comprising rapamycin prepared by processes known pst s& and if desired a pharmaceutically acceptable carrier, diluent or excipient; said composition being adapted for administration orally, parenterally, nasally, or intrabronchially. As such, rapamycin is useful in providing the symptomatic relief of diseases in which pulmonary inflammation is a component such as, asthma, chronic obstructive pulmonary disease, emphysema, acute respiratory distress syndrome, bronchitis, and the like.

The prevention and reversal of pulmonary inflammation by rapamycin was established by the inhibition of pulmonary inflammatory cell influx in an in vivo standard pharmacological test procedure emulating the inflammatory changes observed clinically in chronic asthmatics. The procedure used and results obtained are described below.

Male Hartley guinea pigs (400 - 700 g) that have been fasted overnight are sensitized according to a modification of the method of Dunn et al [Am. Rev. Resp. Dis 137: 541 (1988)]. Guinea pigs receive 1 i.m. injection in each hind leg of 0.35 ml (total volume = 0.7 ml) ovalbumin (OA; 50 mg ml), in isotonic sterile saline. Following a 3 week sensitization period, each animal is pretreated (-1 h) with pyrilamine (2-5 mg/kg i.p.) to prevent hypoxic collapse and death, and then challenged with an aerosol of 0.2% OA (in distilled deionized water) for 3 min using a DeVilbiss Ultra-Neb 100 nebulizer. Drugs or vehicle (0.5% Tween 80) are administered orally in a volume of 1 ml 500 g body wt. at appropriate times pre- and post- OA challenge. Rapamycin was administered orally at -48h, -24h, -lh and +4 hours relative to OA aerosol. Positive control animals were challenged with the OA aerosol, and negative control animals were challenged with an aerosol of distilled water only .

Twenty-four hours later, each animal was humanely sacrificed with an overdose of urethane (60 mg/ml; -10 ml i.p.). The trachea of each animal is isolated and the lungs are lavaged jη situ with three-2Q ml washes of isotonic sterile saline. All samples are kept on ice. This bronchoalveolar lavage fluid from each animal is then centrifuged for 10 min at 400 x g at 5°C. The supernatant is discarded, and each cell pellet is resuspended in 3 ml of isotonic sterile saline. The number of inflammatory cells present was then determined using a Coulter model ZM particle counter. All values are corrected by subtracting the mean ( x ) value of the negative control group from all other individual samples. Percent inhibition values for individual samples are calculated using these corrected cell counts in the following formula:

_«, , . .. . . ~ positive control (corrected) - individual cell count (corrected) _. . _ΛΛ % Inhibition -*• _ X lϋu x positive control (corrected)

Mean % inhibition is determined for each group and expressed as x % iiΛibition ± S E. The ED50S with 95% confidence limits arc calculated [Litchfield, S.T and Wilcoxon, F.A., J. Pharmacol. Exp. Ther. 9_£: 99-113 (1949)].

The following table shows the results obtained for guinea pigs treated with various doses of rapamycin (n = 12 animals per treatment group).

INHIBITION OF PULMONARY INFLAMMATORY CELL INFLUX

The results of this in vivo standard pharmacological test procedure emulating the inflammatory cell changes observed clinically in asthmatics, demonstrates that rapamycin exhibited a dose dependent inhibition of pulmonary inflammatory cell influx with a calculated ED50 (95% C.L.) of 0.2 (0.08 - 0.60) mg kg in response to an antigenic challenge, and is therefore useful in preventing or reversing pulmonary inflammation and in treating disease states in which pulmonary inflammation is a component such as, asthma, chronic obstructive pulmonary disease, emphysema, acute respiratory distress syndrome, bronchitis, and the like.

When rapamycin is employed in the treatment of pulmonary inflammation, it can be formulated into oral dosage forms such as tablets, capsules and the like.

Rapamycin can be administered alone or by combining it with conventional carriers, such as magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low melting wax, cocoa butter and the like. Diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, tablet-disintegrating agents and the like may be employed. Rapamycin may be encapsulated with or without other carriers. In all cases, the proportion of active ingredients in said compositions both solid and liquid will be at least to impart the desired activity thereto on oral administration. Rapamycin may also be injected parenterally, in which case it is used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic. For administration by intranasal or intrabronchial inhalation or insufflation, rapamycin may be formulated into an aqueous or partially aqueous solution, which can then be utilized in the form of an aerosol.

The dosage requirements vary with the particular compositions employed, the route of administration, the severity of the symptoms presented and the particular subject being treated. Based on the results obtained in the standard pharmacological test procedure, projected oral daily dosages of active compound would be 0.01 - 10 mg kg, preferably between 0.1 - 10 mg/kg, and more preferably between 0.3 - 4 mg/kg. Treatment will generally be initiated with small dosages less than the optimum dose of the compound. Thereafter the dosage is increased until the optimum effect under the circumstances is reached; precise dosages for oral, parenteral, nasal, or intrabronchial administration will be determined by the administering physician based on experience with the individual subject treated. In general, rapamycin is most desirably administered at a concentration that will generally afford effective results without causing any harmful or deleterious side effects, and can be administered either as a single unit dose, or if desired, the dosage may be divided into convenient subunits administered at suitable times throughout the day.

Claims

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for preventing or reversing pulmonary inflammation in a mammal which comprises rapamycin prepared by processes known pα sε and if desired a pharmaceutically acceptable carrier, diluent or excipient, said composition being adapted for administration orally, parenterally, intranasally, or intrabronchially.

2. A pharmaceutical composition according to Claim 1 for providing symptomatic relief of asthma, chronic obstructive pulmonary disease, emphysema, acute respiratory distress syndrome, or acute bronchitis in a mammal.

3. A pharmaceutical composition according to Claim 1 or Claim 2 when in unit dose form.

4. A pharmaceutical composition according to Claim 3 in which the unit dose is 0.01 to 10 mg kg based on the weight of the mammal to be treated.

5. A pharmaceutical composition according to Qaim 3 in which the unit dose is 0.1 to 10 mg/kg based on the weight of the mammal to be treated.

6. A pharmaceutical composition according to Claim 3 in which the unit dose is 0.3 to 4 mg kg based on the weight of the mammal to be treated.

7. A method of preventing or reversing pulmonary inflammation in a mammal in need thereof which comprises administering an effective amount of rapamycin orally, parenterally, intranasally, or intrabronchially.

8. The method according to Qaim 7, which comprises administering rapamycin in a daily dose of 0.01 to 10 mg/kg.

9. The method according to Qaim 7, which comprises administering rapamycin in a daily dose of 0.1 to 10 mg/kg.

10. The method according to Qaim 7, which comprises administering rapamycin in a daily dose of 0.3 to 4 mg/kg.

11. A method of providing symptomatic relief of asthma, chronic obstructive pulmonary disease, emphysema, acute respiratory distress syndrome, and acute bronchitis in a mammal in need thereof which comprises administering an effective amount of rapamycin orally, parenterally, intranasally, or intrabronchially.

12. The method according to Qaim 11, which comprises administering rapamycin in a daily dose of 0.01 to 10 mg/kg.

13. The method according to Qaim 11, which comprises administering rapamycin in a daily dose of 0.1 to 10 mg/kg.

14. The method according to Qaim 1 l.which comprises administering rapamycin in a daily dose of 0.3 to 4 mg kg.